ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Durability of Pancreatic Islets Transplantation in Brittle Type 1 Diabetics – 9 Year Follow Up

P. Witkowski, M. Garfinkel, L. Schenck, S. Pannain, J. Thistlethwaite, W. Chon, O. Cochet, K. Golab, O. Savari, J. Millis

Surgery, Medicine, University of Chicago, Chicago, IL
Surgery, Southern Illinois University School of Medicine, Springfield, IL

Meeting: 2013 American Transplant Congress

Abstract number: D1576

Related Abstracts
  • Durability of Pancreatic Islets Transplantation in Brittle Type 1 Diabetics- 10 Year Follow Up
  • Optimization of the Coating of Pancreatic Islets with T Regulatory Cells in the Novel Immunoprotective Approach

The aim of the study was to assess long-term outcomes of the pancreatic islet transplantation. Methods: Human pancreatic islets were administered sequentially in up to 3 separate infusions with the goal of insulin independence. The immunosuppression protocol consisted of IL-2R antibody, rapamycin and tacrolimus. Results: After intensive screening of over 900 patients, only 9 (5.5%) were selected from 163 evaluated as suitable candidates. The main reasons for exclusions were BMI>28 (24%), need for optimization of insulin therapy (20%), self exclusion (15%), and CrCl<80 (14%). Four out of 9 (44%) patients completed the islet transplant protocol. All four patients are currently insulin-free 92, 73, 70, and 59 months after first infusion of total 19+/- 2 kIEQ/kg islet mass. Mean age and BMI was 46+/-3 and 20+/-1, respectively. In this cohort of patients, glycemic control improved dramatically, with elimination of hypoglycemic unawareness, lowering of HbA1C (8.4+/-0.7 to 5.9) and MAGE (5.5+-1.1 to 1.7+-0.3). Additionally, Beta score rose from 1, 1,3, 0 to 8, 8, 8, 7, respectively. None of these patients developed a positive PRA despite multiple islet infusions (up to 3). Rapamicin had to be replaced with antimetabolites in 3 individuals and tacrolimus in remaining one due to complications. None of patient developed proteinuria and average MDRD GFR did not change significantly. All patients did require statins and antihypertensive medications. There was also a large improvement in QoL. Five remaining patients did not complete the transplant protocol. They dropped the study or they were withdrawn after the first infusion secondary to noncompliance, narcotic and alcohol abuse, and/or disappointment with the initial results. Conclusion: Only a small fraction of candidates are suitable for islet transplantation. Careful selection is vital in order to limit high drop out rates. Immunosuppressant medications must be frequently adjusted to facilitate islet survival and long-term health of the recipients. At our institution, pancreatic islet transplantation offered durable long-term insulin free glycemic control in highly selected brittle diabetics without increased risk for sensitization.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Witkowski P, Garfinkel M, Schenck L, Pannain S, Thistlethwaite J, Chon W, Cochet O, Golab K, Savari O, Millis J. Durability of Pancreatic Islets Transplantation in Brittle Type 1 Diabetics – 9 Year Follow Up [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/durability-of-pancreatic-islets-transplantation-in-brittle-type-1-diabetics-9-year-follow-up/. Accessed December 13, 2019.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2019 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

wiley-new-logo

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.